Mundipharma is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds as well as skin irritations.
For more information, visit https://www.mundipharma.com.au
This Quality Improvement (QI) Program aims to improve the management and quality of life in patients taking long-acting opioids and experiencing constipation.
Chronic non-cancer pain can have significant effects on a patient's physical and psychological wellbeing, and requires multimodal and multidisciplinary management approaches tailored to the individual patient. This module explores the process of creating individualised management plans using non-pharmacological and pharmacological approaches where appropriate.
The rescheduling of codeine to a prescription-only medication has resulted in patients who have been taking codeine long-term for chronic pain presenting for prescriptions. This education explores issue surrounding the use of codeine for chronic pain, and how to better manage chronic pain patients through a multidisciplinary approach.